Prasugrel Effient For Acute Coronary Syndrome In People Undergoing Percutaneous Coronary Intervention. One treatment for acs is percutaneous coronary intervention (pci) plus adjunctive treatment with antiplatelet drugs. Dual therapy antiplatelet treatment aspirin plus either prasugrel (efient ®, daiichi sankyo company ltd uk/eli lilly and company ltd), clopidogrel or ticagrelor (brilique ®, astrazeneca) is standard in uk clinical practice.
Baseline clinical characteristics. Overall n=2585 STEMI n ... from www.researchgate.net Jun 22, 2017 · dual antiplatelet therapies with a p2y 12 inhibitor and aspirin have shown to reduce ischemic events and stent thrombosis in patients with acute coronary syndromes (acs) undergoing revascularization. We compared prasugrel and ticagrelor in patients with acute coronary syndrome (acs) undergoing percutaneous coronary intervention (pci). 3.2 the summary of product characteristics for prasugrel states that it should be started with a single 60mg loading dose and then continued at 10mg once a
Undergoing primary or delayed percutaneous coronary intervention.
One treatment for acs is percutaneous coronary intervention (pci) plus adjunctive treatment with antiplatelet drugs. 3.2 the summary of product characteristics for prasugrel states that it should be started with a single 60mg loading dose and then continued at 10mg once a Prasugrel is an alternative to clopidogrel for treating moderate to high risk acute coronary syndromes that are managed by percutaneous coronary intervention in combination with aspirin. Systematic review and economic analysis.
Location:
Share :
Post a Comment
for "Prasugrel Effient For Acute Coronary Syndrome In People Undergoing
Percutaneous Coronary Intervention"
Post a Comment for "Prasugrel Effient For Acute Coronary Syndrome In People Undergoing Percutaneous Coronary Intervention"